The University of Edinburgh
Exploring the cooperation between SOX2 and p53 in glioblastoma
Abstract
dc:description.abstractSOX2 is a critical regulator of several tissue stem cells, including neural stem cells (NSCs) in the forebrain. Glioblastoma (GBM), a high-grade brain cancer, is driven by cancer stem cell-like cells with NSC characteristics. SOX2 is essential for the maintenance of GBM stem cells (GSCs) and is highly expressed across all genetic subtypes of GBM. p53, a tumour suppressor that is frequently mutated in GBM, is associated with enhanced tumour aggressiveness when deleted or mutated. This study explores the roles of SOX2 in glioblastoma and how it interplays with p53 in GBM to contribute to tumour aggressiveness and progression. We first developed a knock-in doxycycline-inducible SOX2 and/or Mdm2 overexpressing mouse NSC lines (into the H11 safe harbour locus) to determine whether SOX2 overexpression is sufficient for the malignant transformation of NSC. We concluded that SOX2 overexpression alone, or with Mdm2 overexpression, is not sufficient to fully transform NSC into malignant GSCs. However, we did uncover a regulatory feedback loop between SOX2 and p53 signalling, suggesting that loss of p53 enables increased levels of SOX2. We next engineered a previously established mouse GSC tumour initiating cell line (Nf1, Pten deletion, plus hEGFRvIII overexpression; termed NPE) with Sox2 overexpression and p53 knockout. With this NPE-SP model, we explored whether increased SOX2 can increase tumour aggressiveness in an already transformed cell context with competent immune system (BL6 syngeneic). Mouse in vivo tumour initiation assays showed that SOX2 results in increased tumour aggressiveness, reducing median survival and immune evasion. Thus, increased SOX2 is not sufficient to transform mouse NSCs, but has important roles in driving more aggressive behaviours once tumours are established. To identify potential mechanisms, we performed RNA-seq analysis and identified thrombospondin-2 (Thbs2) as a key SOX2 target, alongside P2rx7 and Rps6ka1. We propose that this upregulation leads to enhanced extracellular matrix (ECM) remodelling and immune cell infiltration, contributing to tumour progression. This thesis has explored the oncogenic effects of SOX2 in mouse NSCs and a GSC model to further the understanding of SOX2’s role in GBM tumorigenesis and progression. We conclude that elevated levels of SOX2 are likely to be seen when p53 is mutated, and this enhances immune evasion processes via THBS2 and other immune regulator targets.
Degree
thesis:*- Grantor dc:publisher
- The University of Edinburgh
- Year dc:date.issued
- 2025
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Lo, Erika
- Advisors dc:contributor.advisor
-
- Pollard, Steven
- Walmsley, Sarah
Subjects
dc:subject × 6Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Identifier URI
- http://dx.doi.org/10.7488/era/6236